Skip to search formSkip to main contentSkip to account menu

5-dehydrosparteine

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
Highly Cited
2004
Highly Cited
2004
SummarySparteine, an antiarrhythmic and oxytocic drug, is metabolised by N1-oxidation. The sparteine-N1-oxide rearranges with… 
1989
1989
Sparteine oxidation is part of a genetic polymorphism that affects the metabolism of many drugs and is under monogenic control… 
Highly Cited
1986
Highly Cited
1986
In eight patients a sparteine-test was carried out immediately before and after 1 week of treatment with quinidine 600-800 mg day… 
Highly Cited
1986
Highly Cited
1986
The formation of the two major metabolites of the antiarrhythmic and oxytocic drug sparteine (2- and 5-dehydrosparteine) exhibits… 
1986
1986
  • K. Brøsen
  • British journal of clinical pharmacology
  • 1986
  • Corpus ID: 37051048
Sparteine oxidation appeared to be polymorphic in 185 healthy Greenlanders living in Denmark. Six subjects (3.2%) were phenotyped… 
Highly Cited
1985
Highly Cited
1985
Sparteine oxidation was polymorphic among 301 healthy Danish volunteers. Hence 22 subjects or 7.3% were phenotyped as poor… 
Highly Cited
1985
Highly Cited
1985
The ability to oxidize sparteine to form 2‐ and 5‐dehydrosparteine was studied in 154 healthy Ghanaians. Although the urinary… 
Highly Cited
1984
Highly Cited
1984
The frequency of genetically deficient hydroxylation of mephenytoin (M‐defect) was studied in 83 healthy Caucasians living in… 
Highly Cited
1982
Highly Cited
1982
The capacity for sparteine (SP) metabolism was determined in 48 Caucasian subjects by measuring amounts of drug and…